NCT01485146

A Multiple Ascending Dose Study of ETC-1002 in Healthy Subjects

A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ETC-1002 at Doses Above 120 mg/Day in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Esperion Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

This Phase 1, double-blind (sponsor open), placebo controlled study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of ETC-1002 in healthy subjects.

Conditions

• Safety Evaluation of Escalating Doses

Interventions

Type	Name	Description
DRUG	ETC-1002	escalating doses

Timeline

• Start date: 2011-10-25
• Primary completion: 2012-01-25
• Completion: 2012-01-25
• First posted: 2011-12-05
• Last updated: 2019-03-28

Locations

1 site across 1 country: United States